Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies

Stopped early · Phase 1

Conditions studied: Diffuse Large B-cell Lymphoma

In brief

The purpose of this Phase I/II study is to establish the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) and to evaluate the safety, antitumor activity and pharmacokinetic (PK) profile of MAK683 in patients with advanced malignancies such as Diffuse Large B cell Lymphoma (DLBCL), nasopharyngeal carcinoma (NPC) or other advanced solid tumors for whom no further effective standard treatment is available.

Key facts

Study ID

NCT02900651

Run by

Novartis Pharmaceuticals

People needed

139

Starts

2016-10-03

Expected to finish

2024-10-09

Last updated by the study team

2025-08-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Eastern Cooperative Oncology Group (ECOG): 0 to 2
• Relapsed or refractory diffuse large B cell lymphoma with measurable disease as determined by Non-Hodgkin's Lymphoma Cheson response criteria (2014)
• Advanced or recurrent/metastatic solid tumor, including nasopharyngeal carcinoma, castration-resistant prostate cancer, gastric cancer, ovarian clear cell carcinoma and sarcoma, with measurable disease as determined by RECIST 1.1.

You may not qualify if…

• Other malignant diseases than the ones being treated in this study
• Severe and/or uncontrolled medical conditions that in the investigator's opinion could affect the safety of individual or impair the assessment of study result.
• B-cell lymphoma patients who have received prior allogeneic stem cell transplant
• Patient have received anti-cancer therapies within defined time frames prior to the first dose of study treatment
• Symptomatic central nervous system (CNS) involvement which are neurologically unstable or requiring increasing doses of steroids to control.
• Patient having out of range laboratory values defined as:
• Insufficient bone marrow function at screening:
• Platelets ≤ 50,000/mm3
• Hemoglobin (Hgb) ≤ 80 g/L
• Absolute neutrophil count (ANC) ≤ 1000/mm3 2) Insufficient hepatic and renal function at screening:
• ALP, ALT, and AST > 3 x ULN (>5 x ULN if subject has liver metastases)
• Total bilirubin >1.5 x ULN
• Serum creatinine > 1.5 x ULN and/or creatinine clearance ≤ 50 mL/min

Where it is running

• UCSF . — San Francisco, California, United States
• UCLA Santa Monica Hematology Oncology — Santa Monica, California, United States
• Uni Of TX MD Anderson Cancer Cntr Dept of Onc — Houston, Texas, United States
• Novartis Investigative Site — Toronto, Ontario, Canada
• Novartis Investigative Site — Chengdu, Sichuan, China
• Novartis Investigative Site — Shanghai, China
• Novartis Investigative Site — Villejuif, France
• Novartis Investigative Site — Cologne, Germany
• Novartis Investigative Site — Freiburg im Breisgau, Germany
• Novartis Investigative Site — Hong Kong, Hong Kong
• Novartis Investigative Site — Milan, MI, Italy
• Novartis Investigative Site — Rozzano, MI, Italy
• Novartis Investigative Site — Fukuoka, Fukuoka, Japan
• Novartis Investigative Site — Sunto Gun, Shizuoka, Japan
• Novartis Investigative Site — Singapore, Singapore
• Novartis Investigative Site — Madrid, Spain

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.